July 31--Californians with cancer, heart disease, epilepsy and other conditions
have been forced to pay an average of 10 times more than necessary for at least
20 key drugs, according to a report by the California Public Interest Research
Group and Boston-based Community Catalyst.
The report, titled "Top Twenty Pay-for-Delay Drugs: How Drug Industry Payoffs
Delay Generics, Inflate Prices and Hurt Consumers," claims the affected drugs
have been subject to an industry practice called "pay for delay," in which
brand-name pharmaceutical companies pay off generic drug manufacturers to keep
lower-cost equivalents off the market.
For more details, see www.calpirg.org.
(c)2013 The Sacramento Bee (Sacramento, Calif.)
Visit The Sacramento Bee (Sacramento, Calif.) at www.sacbee.com
Distributed by MCT Information Services